Q3 2024 Imunon Inc Earnings Call
Hello everyone, good morning. My name is Mello and I will be your operator today. At this time, I would like to welcome you to Immunon's third quarter 2024 financial results conference call.
All lines have been placed on mute to prevent any background noise.
Following the speaker's prepared remarks, there will be a question and answer session.
At that time, you may press star and 1 on your phone to ask a question.
Please keep in mind, if you are using a speakerphone, you must release your mute function to allow the signal to reach our equipment.
Again, that's star and one to ask a question during the Q&A session.
Speaker Change: I would now like to turn the call over to Kim Golodetz. Please go ahead.
Speaker Change: Thank you and good morning everyone. This is Kim Golodetz with Alliance Advisors IR. Welcome to Immunon's third quarter 2024 financial results and business update conference call.
Speaker Change: During today's call, management will be making forward-looking statements regarding Immunon's expectations and projections about future events. In general, forward-looking statements can be identified by words such as expect, anticipate, believe, or other similar expressions.
Speaker Change: These statements are based on current expectations and are subject to a number of risks and uncertainties, including those set forth in the company's periodic silence with the Securities and Exchange Commission.
Speaker Change: No forward-looking statements can be guaranteed, and actual results may differ materially from such statements.
Thank you. Bye-bye.
Speaker Change: I also caution that the content of this conference call is accurate only as of the date of the live broadcast, November 7, 2024. Immunon undertakes no obligation to revise or update comments made during this call except as required by law.
Speaker Change: With that said, I would like to turn the call over to Dr. Stacy Lindborg, Immunology President and Chief Executive Officer. Stacy?
Thank you, Kim, and good morning, everybody.
Speaker Change: I'd like to begin by noting that Michael Tardugno, the Executive Chairman of our board, and Khursheed Anwer, our Chief Scientific Officer, are both on the line and will be available for Q&A.
Speaker Change: David Gaiero, our Interim Chief Financial Officer, will review our financial results following my remarks.
Speaker Change: Let me start with a punchline and a groundbreaking milestone for Immunon. On July 30th, we announced the results from our large randomized Phase 2 study, Ovation 2, which has the potential to set a new standard in cancer research.
Speaker Change: An improvement in median overall survival 11.1 months, nearly a year compared to the standard of care, a clinically meaningful and unprecedented improvement in first-line treatment.
Speaker Change: For women who were administered PARP inhibitors in the immunon arm, the median overall survival was not yet reached at data lock, indicating that more than half of the patients in the immunon arm are still with us.
with some women approaching the five-year mark since trial initiation.
Speaker Change: Importantly, for those receiving at least 20% of the planned Immunon-001 doses, survival increased by a remarkable 17 months.
Speaker Change: These outcomes are particularly significant in a patient population that has not witnessed an advancement in frontline therapy which extends patients' lives for over 25 years.
Speaker Change: More crucially, Ovation 2 is the first study ever to demonstrate an improvement in overall survival in this context.
For more information visit www.FEMA.gov
Speaker Change: For a deeper dive and to better understand these outcomes, I encourage you to visit our Ovarian Cancer R&D Day presentation from September 18th.
Speaker Change: which is available on our website under the News & Investors tab and then Scientific Presentations.
This R&D day features insights from studies, principal investigators,
Speaker Change: esteemed thought leaders and distinguished Harvard statistics professor and a former NIH and National Cancer Institute IL-12 researcher.
Speaker Change: Their endorsements are compelling and a testament to the significance of the Ovation 2 results.
Speaker Change: You can listen to the entire program or target specific talks and I promise it will be well worth your attention.
Speaker Change: We also announced today the presentation of additional data from Ovation 2 study at the Society for Immunotherapy of Cancer, or CIDSI, the 39th annual meeting taking place in Houston, Texas.
Speaker Change: The Ovation 2 results were so compelling that they accepted our presentation as a late-breaking poster at the meeting after the deadline had passed.
Speaker Change: Results are being presented at the meeting tomorrow by Dr. Jennifer Scalise from Emory University of Medicine, the School of Medicine.
Speaker Change: This is an exceptional opportunity to build awareness and broader awareness of Immunonu 01 and our Phase II trial results among peers and experts in the oncology field.
Speaker Change: Drilling into the data further, we observed consistent benefits in the trial across multiple study endpoints.
Speaker Change: This includes an early treatment effect as shown by progression-free survival, chemotherapy response scores, surgical response scores, and most importantly, in a sustained way through overall survival.
Speaker Change: These data are all in the intent to treat population of 112 patients.
Speaker Change: We expect to report supportive translational data from the trial shortly.
Speaker Change: In summary, the clinically meaningful results with Iminona-01 are truly remarkable and consistent.
Speaker Change: Furthermore, the safety profile has been consistently benign and easily managed.
Speaker Change: The unmet patient need is very high. This is a terrible and difficult to treat cancer with more than a quarter million women diagnosed with the disease globally each year. In the U.S. there are more than 20,000 new diagnoses and about 13,000 deaths every year.
Speaker Change: Ovation 2 accomplished the desired outcome and we know the data were sufficiently strong that our Scientific Advisory Board unequivocally recommends proceeding to a registrational phase 3 trial with the dose studied in phase 2.
Speaker Change: The support of the Scientific Advisor Award was unanimous and unwavering.
For more information visit www.FEMA.gov
Speaker Change: On a commercial note, our prospective product pricing assumptions suggest a U.S. market opportunity for ovarian cancer that exceeds 1.6 billion annually.
Speaker Change: which is far greater as we consider other geographies and clearly in blockbuster territory.
Speaker Change: We've been saying all along that the Phase II outcome was not unexpected.
Speaker Change: Ovation 1, a phase 1 study in the same population, demonstrated unambiguously through translational data that our theroplast technology works.
Speaker Change: The trial showed immunon-driven increases in anti-cancer cytokine levels, such as IL-12 and interferon gamma, and decreases in immunosuppressant biomarkers, such as FOXP3, PD-1, PD-1L, and ID-01.
Speaker Change: In fact, the breadth of translational data from this trial is more than I can highlight given our time today, and I would encourage you to explore them further through the Ovation I manuscript.
Speaker Change: In short, Ovation 1 provides evidence that Theraplas works by effectively recruiting the patient's own immune system to fight cancer.
Speaker Change: Ovation 1 also provides a dose-dependent trend in clinical improvements and an acceptable immunon safety profile with virtually no overlapping toxicity with chemotherapy treatments.
Speaker Change: For those who follow Immunon closely, you know that what makes Immunon-001 unique is the TheraPlus technology.
Speaker Change: ImmunonuO1 is a non-viral gene therapy which delivers IL-12 directly into the microtumor environment causing multiple fold increases in interferon gamma and those of other important cytokines.
and furthermore, producing never-yet-before-seen overall survival data.
Speaker Change: The gene delivery at the tumor site minimizes the toxicity that others have seen with systemic IL-12 injections.
Speaker Change: And our approach has unlocked the door to new treatment frontiers with IL-12 and is generating new hope for patients with ovarian cancer.
For more information, visit www.FEMA.gov
Speaker Change: Turning to the concept of statistical significance, I want to highlight for just a moment the presentation at our R&D day by Dr. L.J. Wei of Harvard University.
Speaker Change: Dr. Wei pioneered a statistical approach that combines information across study endpoints for a more comprehensive evaluation of our treatment.
Speaker Change: He published this method in journals such as New England Journal of Medicine and JAMA, specifically with the methodology applied to oncology studies.
Speaker Change: If you're short on time, I suggest you prioritize Dr. Wei's presentation.
Speaker Change: He independently analyzed Ovation 2 data, combining information from two Kaplan-Meier curves, progression-free survival and overall survival.
Speaker Change: calculating the area under the curve and generating the average time lost due to both undesirable events of ovarian cancer which would be cancer progression and death.
Speaker Change: Dr. Wei's approach has also been successfully used in cardiology and other additional cancer studies.
Speaker Change: And the end result of this analysis showed that ME9001 had a reduction in the area under the curve with a significant p-value of 0.0375.
Speaker Change: His analysis provided statistical evidence that the effect observed in Ovation 2 is likely to be driven by true treatment effect.
Speaker Change: His analysis gives us added confidence in the ability to replicate Ovation 2 findings in Phase 3.
Speaker Change: So where are we with respect to advancing the development of Immuno-01?
Speaker Change: Interactions with FDA are proceeding well and we have asked the agency for an end-of-phase 2 meeting and will meet with them before the end of the month.
Speaker Change: Assuming an agreement with the agency, we remain on track to begin our Phase 3 registration trial in the first quarter of 2025, and we are carefully identifying the requisite capabilities.
Speaker Change: As we are planning it, we expect that the phase 3 trial will enroll approximately 500 women with advanced ovarian cancer and will evaluate ME9001 in a study design that is very similar to phase 2.
Speaker Change: Inclusion criteria are likely to include newly diagnosed patients of at least 18 years of age that are candidates for neoadjuvant chemotherapy.
Speaker Change: with histological evidence of epithelial, ovarian, fallipian tube, or primary peritoneal carcinoma with stage 3c and 4.
Speaker Change: and a performance score of 0, 1 or 2 by Eastern Cooperative Group or ECOG criteria.
Speaker Change: The primary endpoint is expected to be overall survival but of course the final protocol will be finalized with guidance from the FDA.
Speaker Change: Now to the ongoing MRD study which is principally funded by the Breakthrough Cancer Foundation.
Speaker Change: The study is evaluating iminon-001's potential to eliminate minimal residual disease, or MRD, as determined by second-look laparoscopy.
Speaker Change: We're studying this when Immunona-01 is administered in combination with Bioequivalent Avastin and NACT.
Speaker Change: and subjects newly diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer.
Speaker Change: MRD is prognostic for cancer recurrence and as an endpoint may be able to determine the impact of treatment early in the disease.
Speaker Change: An update on this study was provided by the Study Principal Investigator, Dr. Amir Jazari of MD Anderson Cancer Center at our recent Ovarian Cancer R&D Day.
Speaker Change: The study recently added additional clinical trial sites including Memorial Sloan Kettering Cancer Center and Johns Hopkins University.
Speaker Change: And as the first few patients have now reached second look laparoscopy, Dr. Jhaziri will conduct a pilot study to test circulating tumor DNA levels in plasma and peritoneal fluid following treatment using a next generation CT DNA assay.
Speaker Change: The goal is to determine the impact of both immunon and bioequivalent avastin or ON MRD, understanding that positive MRD patients have worse outcomes.
Speaker Change: Switching topics, let's now turn to the Phase 1 proof of concept study for Immunon 101, which utilizes our Placene platform as a seasonal COVID-19 booster vaccine.
Speaker Change: During the second quarter of 2024 we began enrolling participants in the study which is now fully enrolled and all treatments completed.
Speaker Change: We believe the anticipated immunogenicity data, along with superior handling logistics of the Plastine platform, differentiate our vaccine, and we are on track to complete Phase I and report data before the end of the year.
Speaker Change: We've kicked off BD activities and will actively seek a partner to continue development.
Speaker Change: Recall, this trial was not intended to move forward a vaccine in COVID, but instead to serve as a vehicle to efficiently demonstrate proof of concept on this platform.
Speaker Change: With more than 80 new pathogenic viruses discovered since the 1980s, for the right partner, this is an exciting project that can proceed in a multitude of strategic directions.
Speaker Change: As we gear up for our Phase III trial with Immunon-001 and report top-line data from Immunon-101, we've made two strategic hires to fortify our capabilities.
Speaker Change: These appointments have been meticulously considered to address critical needs at this crucial juncture for Immunon.
Speaker Change: We hired Kristin Longobardi as Senior Vice President of Strategic Operations.
Speaker Change: Kristen joins us with over two decades of exceptional experience in enhancing business processes and operations across the biotech and pharmaceutical sectors.
Speaker Change: Most recently, she served as Vice President of Armed Equality Operations and Performance at Biogen.
Speaker Change: We expect Kristen to play a vital role in planning the conduct of the Phase 3 study, making sure it stays on track and on budget.
In addition, we hired Susan Aylward.
Speaker Change: As General Counsel and Corporate Secretary, Susan brings a depth of legal acumen to our team with a background that includes Senior Counsel at Science 37 and various other senior legal roles.
Speaker Change: Our goals include partnering some of our products, for example, Immunon 101, and as in-house legal counsel, Susan will play an important role in ensuring the soundness of any agreement we enter into.
Speaker Change: while also reducing the extraordinary legal cost burden typically incurred in the biotech industry.
Speaker Change: And now I'd like to turn over the call to Dave Gaiero to review our financial results for the third quarter and year to date. Dave?
Dave Gaiero: Thank you, Stacy. Details of Immunon's third quarter 2024 financial results are included in the press release we issued this morning and in our forum 10Q, which we filed today before the market opened.
Dave Gaiero: As of September 30, 2024, Immunon had $10.3 million in cash and cash equivalents.
Dave Gaiero: With our continued focus on strategically managing our cash while continuing to advance our programs, we expect our capital resources to fund operations into the third quarter of 2025.
Dave Gaiero: Research and development expenses were $3.3 million for the third quarter of 2024, compared with $2 million for the third quarter of 2023.
Dave Gaiero: The increase was driven primarily by increased clinical spend related to Ovation 2 and the Placene trial.
Dave Gaiero: General and administrative expenses were $1.7 million in the third quarter of 2024 as compared with $1.9 million in the third quarter of 2023.
Dave Gaiero: Our net loss was $4.9 million, or $0.34 per share, for the third quarter of 2024, as compared with a net loss of $3.5 million, or $0.37 per share, for the third quarter of 2023.
Dave Gaiero: Turning briefly to financial results for the first nine months of 2024. Research and development expenses were $9.4 million for the first nine months of 2024, compared with $7.7 million for the first nine months of 2023.
Dave Gaiero: The increase was driven primarily by increased clinical spend related to Ovation 2 in the Placene trial.
Dave Gaiero: General and administrative expenses were $5.6 million for the first nine months of 2024, as compared with $7.3 million for the first nine months of 2023.
Dave Gaiero: The decrease in G&A expenses in the first nine months of 2024, compared with the first nine months of 2023, was primarily driven by decreased employee-related expenses and decreased professional fees.
Dave Gaiero: Our net loss was $14.6 million, or $1.39 per share, for the first nine months of 2024, as compared with a net loss of $14.6 million, or $1.64 per share, for the first nine months of 2023.
Speaker Change: With that financial review, I'll turn the call back to Stacy.
Thank you, Dave.
Stacy Lindborg: As I mentioned during our last quarterly call, we've taken a number of steps to conserve cash and align our critical needs with available capital.
Dave Gaiero: The pace of Phase 3 will depend on several factors, including access to capital and patient recruitment.
Dave Gaiero: But at this point, we are targeting a regulatory readout by the end of 2029.
Financing the company is necessary to achieve success.
Dave Gaiero: At this junction, and as Dave pointed out, our cash runway, accounting for costs associated with starting the trial in Q1, extends into Q3 of 2025.
Dave Gaiero: We are able to raise funds from our ATM facility and would look for a more substantial raise with investors who see the value of Immunon-001 in ovarian cancer.
Dave Gaiero: Our seasonal COVID-19 vaccine trial is on track to read out before the end of the year and we are actively pursuing acquisition, license, or partnership for this asset to provide non-dilutive funding.
Dave Gaiero: Our Theraplast technology underpins Immunono-01 and this may likely may have an application to other oncology indications such as pancreatic and colon cancers.
Dave Gaiero: These remain interesting areas to pursue should we have the financial resources to do so.
Dave Gaiero: Before I open the call to your questions, I want to remind you of the power of our technology.
Dave Gaiero: ImmunonuO1 allows durable, therapeutic, and dose-dependent production and release of IL-12 into the tumor microenvironment.
Dave Gaiero: The lack of toxicity shows its advantages over other approaches to IL-12.
Dave Gaiero: Such that the ability of Immuno-01 to achieve well-tolerated and durable dose levels of IL-12, along with other anti-cancer cytokines, could usher in the first immunobased gene therapy for ovarian cancer.
I want to leave you with the following thoughts.
Dave Gaiero: We may have in our hands the first and only immunotherapy that's effective for the treatment of ovarian cancer.
Dave Gaiero: We've reported favorable and clinically meaningful top-line results for Ovation 2 in patients with newly diagnosed ovarian cancer.
Dave Gaiero: We're on track to begin our pivotal Ovation III trial in Q1 2025, and we have internal GMP manufacturing capability in place in Huntsville, Alabama.
Dave Gaiero: which will allow us to produce quality product at an order of magnitude lower cost compared to an external CDMO.
For more information, visit www.FEMA.gov
Dave Gaiero: Ovarian cancer represents a multi-billion dollar unmet market and medical need.
Dave Gaiero: And our product has been granted fast-track designation by FDA and orphan drug status has been established in the U.S. and Europe, thus providing additional protected commercial runway.
Dave Gaiero: A second Phase 2 study in advanced ovarian cancer is underway with Immunauta01 plus Sebastien evaluating MRD through second look laparoscopy.
Dave Gaiero: This is largely funded by the Breakthrough Cancer Foundation and will give insights into combination treatment with a Vastan, Biosimilar Vastan, or Bevacizumab.
Dave Gaiero: Our proof-of-concept study is nearing completion with the Placene platform in SARS-CoV-2. And while we wait on the data, recall Immunon 101 has demonstrated a robust immune response in preclinical platform trials.
And our technology offers multiple advantages over current vaccines.
We believe these attributes will be attractive to potential partners.
For more information, visit www.FEMA.gov
Speaker Change: Before opening the call to questions, I'd like to ask Michael, our Executive Chairman, if he has any questions. Michael?
i
Michael, your phone may be muted.
For more information, visit www.FEMA.gov
I'm sorry, it is muted. I don't have any
Speaker Change: And first, thanks for sharing a remarkable and very optimistic update.
In this short tenure of yours at the company...
We've seen the...
The organization be laser-focused.
Speaker Change: streamlined and delivering results that by any standard or measure suggest a significant investment opportunity.
Speaker Change: I believe that we can all agree that the future of Immunon is bright.
Speaker Change: So with that, I'll return it back to the operator who can open it up for questions.
Speaker Change: Thank you. We will now begin the question and answer session.
Speaker Change: To ask a question, you must press star, then 1 on your telephone keypad.
Speaker Change: If you are using a speakerphone, please pick up your handset before pressing the keys.
Speaker Change: To withdraw your question please press star then 2. At this time we will pause momentarily to assemble our roster.
https://www.youtube.com.au
Speaker Change: Our first question comes from David Bautz from DEX. Your line is open.
Speaker Change: Hey, good morning everyone. Stacy, thanks for the overview this morning. It was very helpful.
Speaker Change: percentage of advanced ovarian cancer patients are on PARP inhibitors and are you going to try to match that percentage in the study and I guess kind of a second part to that question would be are there any other treatments that you're going to be looking at in combination with your therapy?
Speaker Change: So we saw about 40% of patients receiving PARP inhibitors in our trial. We think that could go up as high as 50%.
Speaker Change: In Phase 2, the trial worked very well in terms of balance and randomization, but this is something that we are carefully thinking about from a design perspective.
Speaker Change: Women that have HR deficiency, which includes BRCA mutation, have been shown to benefit from PARP inhibitors.
Speaker Change: And that is a component that we will discuss with FDA and plan to bring into our design so that we can ensure there's balance. It is a group that had differentiated efficacy.
And right now that is the plan.
Speaker Change: for treatment. Your second part to the question was, Are there other treatments that we're considering? We're, we're going to have this very explicitly included in our protocol. And again, we'll discuss this with FDA, and we'll get their feedback on on our protocol.
Thank you. Thank you. Thank you.
Speaker Change: Okay as far as financing the study so you're you're ready to launch with the the capital that you have right now
Speaker Change: Is this going to be a finance as you go? Are there thoughts to do a huge financing? How are you thinking about that right now?
Speaker Change: to get the trial up and running and with a good pace of patients enrolling. And in terms of fundraising, the goal is to fund the trial in full.
Speaker Change: We know this will take time, and we're currently looking at the best and investor-friendly means to fully fund the study.
Thank you. I'm glad to be here. Thank you.
Speaker Change: Okay, sounds good. I appreciate you taking the questions. Thank you, David.
Speaker Change: Thank you. Our next question comes from Camp Dollyver from Brookline Capital Markets. Your line is open.
Speaker Change: Great. Good morning and thank you for taking the questions. I'm going to have two questions.
Speaker Change: First, on 101, you mentioned you've started BD activities. Are you at a point where you've had...
Speaker Change: Are there CDAs in place or are you still in the very early steps?
Speaker Change: Yes, so it's premature to offer in-depth comments around the partnership opportunities that
Speaker Change: that we are pursuing, but as you would expect us to do, we have appropriate feelers out, we're working with some very professional people in this regard.
and we're awaiting our data from the proof-of-concept study.
Speaker Change: on ensuring that any partnership or deal really reflects the value of our product and the platform and we do not intend to fill it for a bargain.
Speaker Change: Great, thank you for that. And the second question relates to the phase three trial and your previous comments that
Speaker Change: You're expecting you'll have some interim readouts. Is that still going to be the case?
Speaker Change: Yes, we are. We've given a lot of thought. We've very carefully designed the phase 3 trial with seeking, you know, expertise outside the company.
Speaker Change: Part of having a thoughtful design is I'm really looking to maximize the likelihood of success.
Speaker Change: for a registration trial, assuming that it is effective, which we believe we have very strong confidence based on our data.
Speaker Change: It's also to allow a thoughtful design I think in phase 3 where you have a fatal illness.
Speaker Change: is to allow early reads on data that could allow for an early submission.
for a subgroup and also for the overall trial.
Speaker Change: that know this field very well, and we will be talking about these design components with FDA. But it would very much allow us to align interim decisions for the trial that are really in the best interest of the product.
Speaker Change: and patients long term but also you know with investors that we're that we're talking with.
For more information visit www.FEMA.gov
Speaker Change: Great. And are there, you know, obviously you're finalizing the details, but...
Speaker Change: Fair to say that the $50 million cost estimate you've given previously is pretty good, pretty reliable at this point?
Speaker Change: Yeah, we've done really very thorough top to bottom and, you know, estimates and continue to come back with what we think is a, you know, a really imminently fundable trial and a number that is very attractive when you compare to other trials of this magnitude, you know, in the oncology world. So, so yes, we remain very confident in our, our estimates.
Great. Thank you so much.
Speaker Change: Thank you. As a reminder, if you have a question, please press star, then 1 on your telephone.
Speaker Change: Our next question comes from James Malloy from Allianz Global Partners.
Go ahead.
Speaker Change: Hey guys, good morning. Thank you for taking my questions. I wonder if you walk through some of your expectations coming out of the end of Phase 2 meeting and it would sort of be a good, bad or equivocal meeting with the FDA. And then any thoughts you could share with us?
Speaker Change: In advance of that, we hope or expect the phase three trial design to look like, sort of enrollment timelines and potential interim cut points.
Speaker Change: that we could be looking for. And then the last question would be, would you be able to characterize the partnership environment for either Placene or perhaps even for Immunon-001? I imagine you're getting interest from a larger farmer for that asset as well. Thank you.
Speaker Change: Thank you, James, for the questions. Let me see if I can tick through them. So, expectations.
Speaker Change: For the end of Phase 2 meeting, as is common in the industry, of course, we'll plan to go through our Ovation 2 data, which is really the foundation of our Phase 3 trial.
Speaker Change: and one of the key goals is to discuss the proposal for phase three.
Speaker Change: As I described earlier, there's been a lot of thought that's gone into our proposal that we've shared with them.
Speaker Change: We've chosen to select the definitive endpoint of our primary endpoint overall survival and we expect that will be the endpoint of the trial, but we of course will come out of that discussion really seeking their advice and input.
Speaker Change: The inclusion criteria that kind of tick through a little bit in our in the prepared remarks are very similar to phase two and you know we we really do look forward to a constructive conversation with them.
Um...
Speaker Change: Your second question, I guess, was related to timing. So you can clarify if you had something else in mind, but we are
Speaker Change: planning by having the end of phase two in this month.
Speaker Change: We're intending to have the protocol pulled together by the end of the year and everything that is between that and the first patient enrolled occurring in Q1 of next year. So we've done a lot of work.
Speaker Change: in advance to allow for successful activation of the study and to be able to move quickly.
Thank you.
Speaker Change: The last was characterizing partnership, the partnership environment, and I, you know, we've been very intentional to not get ahead of ourselves.
Speaker Change: given that we know that these discussions, the data that will come out of the one-on-one trial will be very important, and we do not yet have that in our hands.
Speaker Change: So, it's a little premature to talk about the environment. We've really been engaging with people who would be key with making introductions or furthering conversations, you know, that we think will be the most fruitful for us.
Speaker Change: We share your view on that these are likely to also lead to their plus as well as discussions.
Speaker Change: and remain remain open-minded, you know, to continue to think about the, you know, the best investor-friendly means to propel our company forward.
Great, thank you for taking the questions. Thank you, James.
Speaker Change: Thank you. This concludes our question and answer session. I would like to turn the conference back over to the management for any closing remarks.
Speaker Change: Thank you for your questions guys and as we work in providing new treatment options for women with ovarian cancer and this progresses and we seek an opportunity to partner and further the development of our vaccine platform we remain very excited about reporting data from our ongoing clinical studies in the coming months.
Speaker Change: And we look forward to keeping you appraised of our progress. Thank you for joining us today and for your interest in MNUN. Have a great day.
For more information, visit www.FEMA.gov
https://www.youtube.com.action-circlelineartschool.com
Speaker Change: Thank you. The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
Speaker Change: Clang is not a name for a cult, it is a name of a race. FBI division of CESIL, United Kingdom This video was made possible by Support for Overall Entertainment Analyze and edit by Irina Scribar and Vasco to Be Learned more Click on the address on your screen
Special thanks to...
[music]
Speaker Change: Director of Photography, Michael Tardugno Music by Michael Tardugno Art Direction by Michael Tardugno Music by Michael Tardugno Art Direction by Michael Tardugno
[music]
[music]